Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Tacrolimus (FK 506) in the management of refractory corneal graft rejection in high-risk keratoplasty

Poster Details

First Author: Y.Fernandez Barrientos SPAIN

Co Author(s):    A. Alberte Gonzalez   J. Garrido Linares   S. Gismero Moreno   M. Lorenzo Soto           

Abstract Details

Purpose:

To report the efficacy of Tacrolimus (FK 506; Prograf, Fujisawa Ltd., London) in the treatment of refractory graft rejection and survival of the grat in two cases of high risk penetrating keratoplasty.

Setting:

Hospital Costa del Sol, Marbella, Spain.

Methods:

Case 1 was a patient with ocular rosacea, more than 2 quadrants neovascularization, and a second corneal regraft postoperatory treated with topical and systemic cyclosporine (CsA), 5months after surgery an immune graft rejection was diagnosed. Second case was a 30-years old patient with keratoconus, psoriasis and atopy, an immune rejection with atopic sclerokeratitis was observed 4 months after penetrating keratoplasty.

Results:

Long term survival of the corneal grafts with corrected visual acuities upper 20/40 was observed in both cases under tacrolimus treatment. In case 1 treatment with systemic tacrolimus 5mg/day (blood levels between 6 and 7 ng/ml) and topical tacrolimus 0.02% three times a day, and in case 2 topical tacrolimus 0.02% twice a day, has been maintained, and has had no further rejection episodes. Second eye has been successfully operated of KP in both cases one year after the first graft. No local adverse effects were observed with this topical formulation of local tacrolimus eye drops 0.02%.

Conclusions:

Tacrolimus FK 506 topical and systemic was effective in maintenance clear graft in these cases of high-risk keratoplaty.

Financial Disclosure:

NONE

Back to Poster listing